EU backs use of Novo Nordisk's weight loss drug in adolescents

FILE PHOTO: FILE PHOTO: The logo of Danish multinational pharmaceutical company Novo Nordisk is pictured on the facade of a production plant in Chartres, north-central France, April 21, 2016. REUTERS/Guillaume Souvant/

(Reuters) -The European Medicines Agency said on Friday its committee has recommended expanding the use of Danish drugmaker Novo Nordisk's weight loss drug in adolescents aged 12 years and older.

The drugmaker told Reuters the Committee for Medicinal Products for Human Use's (CHMP) positive opinion was an "important recognition of the unmet medical need among adolescents living with obesity and the need for additional treatment options".